Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
You can paste this link into an email or message to share this resource with your patient.
Chronic kidney disease (CKD) is a major health concern in Australia and is associated with significant morbidity and mortality. CKD is often accompanied by multiple co-morbidities including hypertension, anaemia, hyperparathyroidism and renal osteodystrophy.
Anaemia commonly occurs in people living with CKD due to reduced production of erythropoietin by the kidney. Erythropoiesis stimulating agents (ESA) can help in the management of anaemia associated with CKD. More information about ESAs can be found on this website.
AmgenPro is intended for healthcare professionals in Australia
Login or create an AmgenPro account to access the latest updates on our products, medical resources and patient programs.